GlaxoSmithKline plc (ADR)  

(Public, NYSE:GSK)   Watch this stock  
Find more results for GSK
42.71
+0.70 (1.67%)
Pre-market: 42.90 +0.19 (0.44%)
May 25, 4:07AM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 42.54 - 42.79
52 week 37.24 - 45.49
Open 42.58
Vol / Avg. 0.00/3.14M
Mkt cap 103.27B
P/E 8.45
Div/yield 0.55/5.47
EPS 5.06
Shares 4.87B
Beta 0.79
Inst. own 4%
Jul 27, 2016
Q2 2016 GlaxoSmithKline PLC Earnings Release Add to calendar
May 6, 2016
GlaxoSmithKline PLC Annual Shareholders Meeting (Estimated)
May 5, 2016
GlaxoSmithKline PLC Annual Shareholders Meeting
Apr 27, 2016
Q1 2016 GlaxoSmithKline PLC Earnings Call
Apr 27, 2016
Q1 2016 GlaxoSmithKline PLC Earnings Release
Mar 1, 2016
GlaxoSmithKline PLC at Credit Suisse One-on-One Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -6.81% 35.00%
Operating margin -4.02% 46.67%
EBITD margin - 32.04%
Return on average assets -3.22% 17.79%
Return on average equity -26.93% 179.63%
Employees 101,192 -
CDP Score - 100 B

Address

980 Great West Road
BRENTFORD, TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Officers and directors

Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 50
Bio & Compensation  - Reuters
Simon Dingemans Chief Financial Officer, Executive Director
Age: 51
Bio & Compensation  - Reuters
Moncef Slaoui Chairman - Global Vaccines, Executive Director
Age: 55
Bio & Compensation  - Reuters
Roger Connor President - Global Manufacturing & Supply
Bio & Compensation  - Reuters
Abbas Hussain President, Global Pharmaceuticals
Bio & Compensation  - Reuters
Shah Abbas Hussain President - Europe, Japan & EMAP
Age: 49
Bio & Compensation  - Reuters
Patrick Vallance President - Pharmaceuticals R&D
Bio & Compensation  - Reuters
Emma Walmsley President - Consumer Healthcare Worldwide
Bio & Compensation  - Reuters
Daniel Troy Senior Vice President, General Counsel
Bio & Compensation  - Reuters
Claire Thomas Senior Vice President - Human Resources
Bio & Compensation  - Reuters